These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 17374841)

  • 1. Re: Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability.
    Etzioni RD; Ankerst DP; Thompson IM
    J Natl Cancer Inst; 2007 Mar; 99(6):489-90; author reply 490. PubMed ID: 17374841
    [No Abstract]   [Full Text] [Related]  

  • 2. Prostate-specific antigen (PSA) and PSA velocity: competitors or collaborators in the prediction of curable and clinically significant prostate cancer.
    D'Amico AV
    J Clin Oncol; 2008 Feb; 26(6):823-4. PubMed ID: 18281649
    [No Abstract]   [Full Text] [Related]  

  • 3. [Detection of prostate cancer: yes or no?].
    Van Cangh PJ
    Bull Mem Acad R Med Belg; 2006; 161(3-4):159-69. PubMed ID: 17172224
    [No Abstract]   [Full Text] [Related]  

  • 4. Prostate cancer: 4. Screening.
    Meyer F; Fradet Y
    CMAJ; 1998 Oct; 159(8):968-72. PubMed ID: 9834724
    [No Abstract]   [Full Text] [Related]  

  • 5. Long-term prediction of prostate cancer: prostate-specific antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representative, unscreened population.
    Ulmert D; Serio AM; O'Brien MF; Becker C; Eastham JA; Scardino PT; Björk T; Berglund G; Vickers AJ; Lilja H
    J Clin Oncol; 2008 Feb; 26(6):835-41. PubMed ID: 18281654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PSA doubling time as a predictive factor on repeat biopsy for detection of prostate cancer.
    Shimbo M; Tomioka S; Sasaki M; Shima T; Suzuki N; Murakami S; Nakatsu H; Shimazaki J
    Jpn J Clin Oncol; 2009 Nov; 39(11):727-31. PubMed ID: 19674994
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of free prostate-specific antigen measurement in prostate-specific antigen screening for prostate cancer.
    Johnson L
    Clin Prostate Cancer; 2002 Dec; 1(3):142-4. PubMed ID: 15046688
    [No Abstract]   [Full Text] [Related]  

  • 8. Inverse association between histologic inflammation in needle biopsy specimens and prostate cancer in men with serum PSA of 10-50 ng/mL.
    Terakawa T; Miyake H; Kanomata N; Kumano M; Takenaka A; Fujisawao M
    Urology; 2008 Dec; 72(6):1194-7. PubMed ID: 18829081
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate specific antigen velocity in men with total prostate specific antigen less than 4 ng/ml.
    Loeb S; Roehl KA; Nadler RB; Yu X; Catalona WJ
    J Urol; 2007 Dec; 178(6):2348-52; discussion 2352-3. PubMed ID: 17936844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Re: Correction of prostate-specific antigen velocity for variation may improve prediction of cancer following prostate repeat biopsy.
    Singh A
    Can J Urol; 2009 Jun; 16(3):4659. PubMed ID: 19497173
    [No Abstract]   [Full Text] [Related]  

  • 11. Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability.
    Carter HB; Ferrucci L; Kettermann A; Landis P; Wright EJ; Epstein JI; Trock BJ; Metter EJ
    J Natl Cancer Inst; 2006 Nov; 98(21):1521-7. PubMed ID: 17077354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate-specific antigen and prostate cancer prognosis.
    Church TR
    J Natl Cancer Inst; 2006 Nov; 98(21):1509-10. PubMed ID: 17077347
    [No Abstract]   [Full Text] [Related]  

  • 13. Pretreatment prostate-specific antigen velocity and the risk of death from prostate cancer in the individual with low-risk prostate cancer.
    D'Amico AV; Chen MH
    J Clin Oncol; 2009 Aug; 27(22):3575-6. PubMed ID: 19506151
    [No Abstract]   [Full Text] [Related]  

  • 14. Is prostate-specific antigen velocity useful in early detection of prostate cancer? A critical appraisal of the evidence.
    Etzioni RD; Ankerst DP; Weiss NS; Inoue LY; Thompson IM
    J Natl Cancer Inst; 2007 Oct; 99(20):1510-5. PubMed ID: 17925534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Re: Complexed prostate specific antigen provides significant enhancement of specificity compared with total prostate specific antigen for detecting prostate cancer.
    Stephan C; Jung K; Lein M; Schnorr D; Loening SA
    J Urol; 2000 Nov; 164(5):1671-2. PubMed ID: 11203074
    [No Abstract]   [Full Text] [Related]  

  • 16. Can we accurately identify men with low risk prostate cancer?
    Neal DE
    J Urol; 2008 Oct; 180(4):1217-8. PubMed ID: 18707718
    [No Abstract]   [Full Text] [Related]  

  • 17. Controversy in clinical cancer screening--prostate-specific antigen.
    McKay DA
    West J Med; 1994 Jul; 161(1):58-9. PubMed ID: 7524244
    [No Abstract]   [Full Text] [Related]  

  • 18. The relationship between anxiety and time to treatment for patients with prostate cancer on surveillance.
    Latini DM; Hart SL; Knight SJ; Cowan JE; Ross PL; Duchane J; Carroll PR;
    J Urol; 2007 Sep; 178(3 Pt 1):826-31; discussion 831-2. PubMed ID: 17632144
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Prostate-specific membrane antigen and its role in diagnosis of prostate cancer].
    Chekhonin VP; Grigor'ev ME; Zhirkov IuA; Lebedev DV
    Vopr Med Khim; 2002; 48(1):31-43. PubMed ID: 12068496
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Percent free prostate specific antigen does not enhance the specificity of total prostate specific antigen for the detection of prostate cancer in Korean men 50 to 65 years old: a prospective multicenter study.
    Jeong IG; Lee KH;
    J Urol; 2008 Jan; 179(1):111-6. PubMed ID: 17997422
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.